You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞銀窩輪》本年度最後期結日 搏低位撈底可留意美團認購16886、快手認購19164
港股周四,亦是本年度最後一個期結日,港股微升43點後,恆指再升約百點上試23250點,其後回吐,曾失守23000點;下午時段恆指稍有起色,最終全日微升25點,收報23112點,市場整體繼續偏靜市,望港股通下周二啟市後市場投資氣氛可受帶動。 ATMX中美團(3690)、小米(1810)有微升幅。美團較早前公佈與快手(1024)達成戰略合作關係,美團將在快手平台上線美團小程序,其商家從而可以通過平台提供套餐、代金券、甚至預訂、線上交易、售後服務等一條龍服務予快手用戶。惟消息公佈後,美團及快手股價都有下跌趨勢,美團截至周四終於止跌,全日升1.1%,收報218.4港元,逐漸邁向四個月以來低位(八月下旬時的193.4港元)。至於快手,與美團合作的消息沒有帶動其股價,周四續跌0.6%,收報68.1港元,愈見迫近八月中旬時上市新低的水平(收報約65.8港元)。如投資者希望趁低位撈底搏美團、快手股價反彈,看好美團,可留意美團認購16886,行使價269.08港元,22年3月到期,有效槓桿約6.9倍。如投資者看好快手,可留意快手認購19164,行使價92.55港元,22年9月到期,有效槓桿約2.9倍。 普遍周四大部分恆指成分股沒有大上落,藥明(2269)早段時候曾下跌約3.8%至84港元,其後發力追落後,最終上升近3%,重上90港元關口收市,亦是全日升幅最多的恆指成分股。藥明本月中因疑被納入投資黑名單致令股價暴跌逾兩成,其後獲確認不會被納入黑名單,股價已經開始回穩;最新藥明公佈啟動回購344.8萬股的股份,金額達3億元,帶動股價再向上升,挑戰90港元更高的水平。根據瑞銀周四記錄,較多投資者以牛熊證作部署。如投資者看好藥明,可留意藥明牛證60038,收回價80港元,行使價78.5港元,22年7月到期,有效槓桿約7倍。如投資者看淡藥明,可留意藥明熊證60751,收回價100港元,行使價101.5港元,22年7月到期,有效槓桿約7.3倍。 更多窩輪牛熊資訊:瑞銀認股證牛熊證網站:http://www.ubs.com/hkwarrants 窩證教學及巿焦點況短片: https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber 謝宛彤 瑞銀亞洲股票衍生產品銷售部 本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2021。版權所有。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account